Short Interest in Roche Holding AG (OTCMKTS:RHHBY) Increases By 25.2%

Roche Holding AG (OTCMKTS:RHHBY) saw a significant increase in short interest in October. As of October 15th, there was short interest totalling 3,246,800 shares, an increase of 25.2% from the September 30th total of 2,593,100 shares. Based on an average trading volume of 2,151,600 shares, the days-to-cover ratio is currently 1.5 days.

Institutional Trading of Roche

Institutional investors have recently bought and sold shares of the business. AlphaMark Advisors LLC acquired a new stake in shares of Roche in the first quarter worth approximately $34,000. GAMMA Investing LLC boosted its stake in shares of Roche by 61.5% in the second quarter. GAMMA Investing LLC now owns 5,038 shares of the company’s stock worth $175,000 after acquiring an additional 1,919 shares during the last quarter. Archer Investment Corp boosted its stake in shares of Roche by 10.6% in the second quarter. Archer Investment Corp now owns 6,810 shares of the company’s stock worth $236,000 after acquiring an additional 652 shares during the last quarter. Waldron Private Wealth LLC acquired a new position in Roche during the second quarter worth $263,000. Finally, Lee Danner & Bass Inc. acquired a new position in Roche during the second quarter worth $327,000.

Roche Stock Down 0.6 %

RHHBY traded down $0.26 during trading on Monday, hitting $40.31. The company’s stock had a trading volume of 1,322,891 shares, compared to its average volume of 2,167,814. Roche has a twelve month low of $29.20 and a twelve month high of $42.43. The business’s fifty day simple moving average is $39.93 and its 200 day simple moving average is $36.35.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on RHHBY. Deutsche Bank Aktiengesellschaft cut Roche from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Bank of America raised Roche from a “neutral” rating to a “buy” rating in a report on Friday, September 13th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Roche presently has an average rating of “Hold”.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.